The History of Johnson & Johnson Talc Litigation

3/19/2026

Huge J&J Talc Punitive Damages Award Reduced

On March 13, Los Angeles County Superior Court Judge Ruth Ann Kwan granted Johnson and Johnson’s motion for judgment notwithstanding the verdict as to the $950 million punitive damages awarded by a Los Angeles jury on October 6,2025 to the estate of Mae Moore. Ms. Moore’s estate had filed a lawsuit alleging that her mesothelioma was caused by her daily use of J&J’s talc products over a more than 80-year period. The jury in that trial determined that the pharmaceutical giant’s talc products contained asbestos and that the plaintiff’s use of the products contributed to her mesothelioma. They also found that J&J was negligent and had failed to warn consumers of the known risks inherent in the use of the talc products; they ultimately awarded $16 million in compensatory damages and an additional $950 million in punitive damages.

In her order reducing the punitive award, Judge Kwan wrote:

Upon considering the entire record in the light most favorable to plaintiffs, the Court grants JNOV as to punitive damages because plaintiffs did not establish – by clear and convincing evidence – that J&J acted with malice.

Contrary to the jury’s findings, she also found that J&J did not intend to deceive Ms. Moore or conceal knowledge that its talc contained asbestos “because there is no substantial evidence of a preexisting relationship giving rise to a duty to disclose, which is an essential element” of the cause of action. The judge also ruled that the amount of the punitive damages award was unconstitutionally excessive. However, she did not grant J&J’s motion as to causation.

J&J responded to the ruling by contending the trial court:

“…..appropriately threw out the $950 million punitive damages award secured by the plaintiff lawyers’ misleading presentation, as it was devoid of evidentiary support and patently unconstitutional. After reviewing the full trial record, the trial court correctly concluded that decades of extensive testing showing Johnson & Johnson’s cosmetic talc products did not contain—and the company had no reason to believe they contained—any asbestos.  As matter of law, therefore, the punitive damages cannot stand, which is the same reasoning and conclusion that applies to any punitive award rendered against the company.”

J&J intends to file an appeal with regard to the remaining claims in this case. Similarly, plaintiff’s counsel has promised to appeal the trial court’s ruling.

2/19/2026

J&J Found Liable for $250K Verdict in Philadelphia

On Friday, February 13, a Philadelphia jury found Johnson & Johnson liable for the death of a woman who developed ovarian cancer after decades of using baby powder manufactured by the pharmaceutical giant, awarding the plaintiff $250, 000. The amount was broken out into $50,000 in compensatory damages and $200,000 in punitive damages.  During the three-week trial, counsel for plaintiff Gayle Emerson argued that her use of J&J’s powder was a contributing factor to her developing fatal ovarian cancer; Ms. Emerson died in 2019 shortly after she filed the lawsuit. The trial was the second to be held in Philadelphia and the first in five years, because of a stay that was instituted to work out J&J’s bankruptcy issues, focused on the separate unit J&J had created and immediately spun off to handle the company’s talc liabilities. Although the award was far less than recent verdicts involving the company’s talc products, counsel for the plaintiff maintained that the jury had found J&J directly liable on all claims for the Ms. Emerson’s death. In response, counsel for the defendant attributed the plaintiff’s cancer to her pre-existing health history, which included a prior ovarian cystectomy and hysterectomy, her weight, and a douche product she had used for several years.

Erik Haas, representative for J&J, said in a separate statement:

“This token verdict reflects the jury’s appreciation that the claims were meritless and divorced from the science. While nominal, the award reflects the inequity of the current jury system where, as here, plaintiff’s lawyers and their experts failed to legally or scientifically address the evidence demonstrating the true cause of plaintiff’s cancer was unrelated to the company’s products.  That fundamental failure of proof, among others, will be a central ground for our appeal, which we will immediately pursue.”

Haas also state that the company would appeal the verdict.

Prior verdicts involving J&J talc products have resulted in much larger verdicts, including a $966 million verdict in October 2025 in California, and a series of verdicts in December 2025, including a $1.5 billion verdict in Baltimore, a $65.5 million verdict in Minnesota and a $40 million verdict awarded to two women in California.

A previous trial held in Philadelphia in 2021 had resulted in a defense verdict for the company. The Emerson case is one of 176 lawsuits pending in Philadelphia that make similar allegations that J&J’s talc powder is contaminated with asbestos, a fact of which the company has long been aware. There are also nearly 68,000 lawsuits pending in federal court that are part of a multidistrict litigation proceeding in New Jersey. The first bellwether case in the federal MDL is scheduled to proceed later this year.

2/2/2026

Johnson and Johnson Talc Trial Opens in Philadelphia

A trial is currently underway in Philadelphia Court of Common Pleas against manufacturer Johnson & Johnson, one of 175 talc cases pending in Philadelphia against the pharmaceutical giant in which plaintiffs claim that the company’s flagship baby powder product was contaminated with asbestos, causing ovarian cancer.  The current lawsuit is the first to proceed since J&J spun off its talc unit and unsuccessfully attempted three times to file Chapter 11 bankruptcy.

The case was filed by Gayle Emerson, who alleged that her daily use of J&J baby powder for nearly 50 years caused her to develop ovarian cancer. Counsel for Ms. Emerson argues that J&J was aware that its baby powder was contaminated but failed to warn consumers and continued to market its product despite knowing that the talc, mined in Vermont, Italy and China was mined from ground known to be crossed with veins of asbestos ore.

Johnson and Johnson maintains that its product is not contaminated and does not cause ovarian cancer. Counsel for the company argues that plaintiff’s cancer was more likely caused by other factors given her medical history, including her age, obesity and use of a douche product for nearly the same length of time as her powder use.

The trial is expected to last three weeks. The only other talc trial held in Philadelphia in 2021 resulted in a defense verdict for J&J. A third trial is scheduled for April.

In related news, retired U.S. District Judge Freda Wolfson, serving as special master, denied most of 17 motions filed and recommended that most of the 39 experts identified by both the plaintiffs and the defendant J&J in the federal talc MDL should be permitted to testify. Presiding Judge Michael Shipp, who took over the MDL in 2023 after Judge Wolfson retired had allowed both sides to reargue the issue of experts in light of the amendment to Federal Rule of Evidence 702 which created a path for the company to challenge the reliability of the scientific evidence being offered by the plaintiffs. In a 639-page report Judge Wolfson concluded that the experts for the plaintiffs should be permitted to testify regarding the link between J&J’s baby powder product and the plaintiffs developing ovarian cancer.

12/22/2025

Baltimore Jury Orders $1.5 Billion Verdict in Johnson & Johnson Talc Case

A Baltimore City jury has delivered a significant verdict in ongoing talc litigation, ordering Johnson & Johnson and related entities to pay more than $1.5 billion to a plaintiff who alleged long-term exposure to asbestos contaminated talc products caused her cancer.

On December 22, jurors in the Circuit Court for Baltimore City found Johnson & Johnson, two of its subsidiaries, and spinoff Kenvue liable for failing to warn the plaintiff, Cherie Craft, that the company’s talc-based baby powder contained asbestos. Craft alleged that decades of exposure to these products led to her diagnosis of peritoneal mesothelioma, a rare and aggressive cancer commonly associated with asbestos exposure.

Key Takeaways from the Verdict

The jury concluded that Johnson & Johnson and its related entities failed to provide adequate warnings despite knowledge of asbestos risks associated with talc. The verdict reinforces several trends shaping the talc litigation landscape:

• Jury skepticism of asbestos risk disclosures
  Jurors continue to scrutinize historical product testing, corporate knowledge, and internal communications related to asbestos contamination in consumer products.
• Expanded liability across corporate entities
  In addition to Johnson & Johnson and its subsidiaries, liability extended to Kenvue, underscoring the complexity of corporate structures and spinoffs in mass tort litigation.
• Continued momentum despite bankruptcy strategies
  This verdict follows multiple unsuccessful attempts by Johnson & Johnson to resolve talc claims through bankruptcy proceedings, signaling that jury trials remain a critical pressure point in global settlement negotiations.

Implications for Talc and Asbestos Litigation

This decision adds to a growing body of high-value verdicts that may influence settlement dynamics across the broader talc docket. For plaintiff firms, the case highlights the importance of:

• Detailed exposure histories spanning decades.
• Medical documentation tying asbestos exposure to specific disease pathways.
• Robust product identification and usage timelines
• Clear, well-organized evidentiary presentation for juries

For defendants and settlement administrators, the ruling underscores the operational challenges of managing large claimant populations, evaluating claim validity, and forecasting financial exposure as cases move toward resolution.

Looking Ahead

As talc litigation continues to evolve, verdicts like this one will accelerate discussions around global resolution frameworks, compensation matrices, and claim validation standards. Courts, counsel, and claims administrators alike are facing increased pressure to manage complexity at scale while maintaining transparency and consistency.

At Verus, we collaborate with firms navigating large-scale asbestos and talc matters by supporting claimant intake, data validation, medical audits, analytics, and settlement administration, helping legal teams prepare for both trial and resolution-driven outcomes.

10/21/2025

Johnson & Johnson Hit With $966 Million Verdict in Talc Cancer Case 

On October 6, a Los Angeles jury awarded $966 million to the family of a woman who claimed that her mesothelioma was caused by asbestos-contaminated talc products manufactured by pharmaceutical giant, Johnson & Johnson; Mae Moore was a California resident who died of the rare cancer in 2021, a year after she filed suit against the company. The jury allocated $16 million in compensatory damages and an additional $950 million in punitive damages. Although Ms. Moore filed her lawsuit in 2021, J&J’s repeated efforts to achieve a bankruptcy settlement that would include the thousands of pending claims filed against it delayed the proceedings. 

In its findings, the jury determined that J&J had concealed the risks inherent in using its baby powder products which was a main factor in causing the plaintiff’s mesothelioma; the jury also agreed that J&J acted with malice by failing to protect the users of its product.  In her complaint, Ms. Moore pointed out that J&J has been testing its talc products for impurities since the 1950s, and that a number of those tests revealed that the products were contaminated by asbestos.  

In response to the outsized verdict, Erik Haas, J&J’s litigation chief stated:  

“We will immediately appeal this egregious and unconstitutional verdict that is directly at odds—in result and amount—with the vast majority of other talc cases wherein the Company has prevailed, including the defense verdict last week against the same plaintiff law firm that brought this baseless action.” 

The company further argued that the case brought by Ms. Moore was based on “junk science” that never should have been presented to the jury.  

For a number of years, J&J has maintained that its baby powder does not contain asbestos or cause cancer.  Notwithstanding their position, the company stopped selling talc-based baby powder in 2020, switching instead to cornstarch-based products. 

The most recent verdict may be reduced on appeal since the U.S. Supreme Court has ruled that punitive damages should, as a rule, be no more than nine times any compensatory award.  

Going forward, in the wake of the dismissal of J&J’s third attempt to resolve nearly 90,000 talcum powder lawsuits through a Chapter 11 settlement worth $9 billion, the company decided to return to the tort system and try cases on an individual basis where results have been mixed. J&J has won 16 out of the last 17 cases that went to trial but losses have been significant; including a $4.7 billion award to 22 women suffering from ovarian cancer in 2018 that was reduced by the appeals court to $2.1 billion.

The litigation surrounding Johnson & Johnson’s (J&J) talc-based products, primarily Baby Powder, represents one of the most significant and protracted mass tort cases in recent history. Allegations that these products caused ovarian cancer and mesothelioma due to asbestos contamination have led to tens of thousands of lawsuits, including a recent $8 million verdict in Massachusetts in June 2025 for a woman who alleged mesothelioma caused by J&J’s talc products. This ongoing legal battle has seen a mix of high-stakes jury trials, substantial verdicts, controversial bankruptcy strategies, and ongoing legal complexities. This article provides a comprehensive history of the J&J talc litigation, tracing its key developments, legal maneuvers, and the challenges faced by both the company and the claimants.

Johnson & Johnson Hit With $966 Million Verdict in Talc Cancer Case 

On October 6, a Los Angeles jury awarded $966 million to the family of a woman who claimed that her mesothelioma was caused by asbestos-contaminated talc products manufactured by pharmaceutical giant, Johnson & Johnson; Mae Moore was a California resident who died of the rare cancer in 2021, a year after she filed suit against the company. The jury allocated $16 million in compensatory damages and an additional $950 million in punitive damages. Although Ms. Moore filed her lawsuit in 2021, J&J’s repeated efforts to achieve a bankruptcy settlement that would include the thousands of pending claims filed against it delayed the proceedings. 

In its findings, the jury determined that J&J had concealed the risks inherent in using its baby powder products which was a main factor in causing the plaintiff’s mesothelioma; the jury also agreed that J&J acted with malice by failing to protect the users of its product.  In her complaint, Ms. Moore pointed out that J&J has been testing its talc products for impurities since the 1950s, and that a number of those tests revealed that the products were contaminated by asbestos.  

In response to the outsized verdict, Erik Haas, J&J’s litigation chief stated:  

“We will immediately appeal this egregious and unconstitutional verdict that is directly at odds—in result and amount—with the vast majority of other talc cases wherein the Company has prevailed, including the defense verdict last week against the same plaintiff law firm that brought this baseless action.” 

The company further argued that the case brought by Ms. Moore was based on “junk science” that never should have been presented to the jury.  

For a number of years, J&J has maintained that its baby powder does not contain asbestos or cause cancer.  Notwithstanding their position, the company stopped selling talc-based baby powder in 2020, switching instead to cornstarch-based products. 

The most recent verdict may be reduced on appeal since the U.S. Supreme Court has ruled that punitive damages should, as a rule, be no more than nine times any compensatory award.  

Going forward, in the wake of the dismissal of J&J’s third attempt to resolve nearly 90,000 talcum powder lawsuits through a Chapter 11 settlement worth $9 billion, the company decided to return to the tort system and try cases on an individual basis where results have been mixed. J&J has won 16 out of the last 17 cases that went to trial but losses have been significant; including a $4.7 billion award to 22 women suffering from ovarian cancer in 2018 that was reduced by the appeals court to $2.1 billion.

The litigation surrounding Johnson & Johnson’s (J&J) talc-based products, primarily Baby Powder, represents one of the most significant and protracted mass tort cases in recent history. Allegations that these products caused ovarian cancer and mesothelioma due to asbestos contamination have led to tens of thousands of lawsuits, including a recent $8 million verdict in Massachusetts in June 2025 for a woman who alleged mesothelioma caused by J&J’s talc products. This ongoing legal battle has seen a mix of high-stakes jury trials, substantial verdicts, controversial bankruptcy strategies, and ongoing legal complexities. This article provides a comprehensive history of the J&J talc litigation, tracing its key developments, legal maneuvers, and the challenges faced by both the company and the claimants.

For insights into effective case management strategies applicable to complex litigations like this, see our article on Complex Case Management Lessons from the J&J Talc Litigation.

The foundation of the J&J talc litigation lies in allegations that the company’s talc-based products, most notably Baby Powder and Shower to Shower, contained asbestos fibers. Plaintiffs contend that decades of use of these products led to the development of serious cancers, including ovarian cancer in women and mesothelioma, a rare cancer usually linked to asbestos exposure. These claims often cite internal documents allegedly showing that J&J was aware of potential contamination as early as the 1970s but failed to warn consumers. The scientific basis for these claims has been a central point of contention throughout the litigation, with plaintiffs presenting expert testimony linking talc and asbestos to cancer, while J&J has consistently argued that its products were safe and that the plaintiffs’ scientific evidence is flawed.

The talc litigation gained significant public attention with early jury verdicts against J&J. One notable case was the landmark 2018 verdict in St. Louis, Missouri, where a jury initially awarded $4.69 billion to 22 women who claimed J&J’s talc products caused their ovarian cancer. While this verdict was later reduced on appeal to $2.12 billion, it signaled a potential turning point and prompted thousands more plaintiffs to come forward. These early trials often involved the presentation of internal J&J documents and expert testimony regarding the presence of asbestos in talc and its potential carcinogenic effects. However, J&J also secured defense verdicts in some early cases, highlighting the ongoing battle over scientific evidence and causation.

As the J&J talc litigation progresses and potential settlements arise, efficient and expert settlement administration becomes crucial. Verus offers comprehensive services to manage all aspects of settlement processes, ensuring accuracy, fairness, and timely distribution of funds.

Faced with mounting liabilities from the tens of thousands of pending lawsuits, Johnson & Johnson implemented a controversial legal maneuver known as the “Texas two-step.” This strategy involved creating a new subsidiary, LTL Management LLC, in Texas, to which J&J transferred all of its talc-related liabilities. Subsequently, LTL Management filed for Chapter 11 bankruptcy in North Carolina, a venue initially perceived as more favorable for such proceedings. The aim of this strategy was to consolidate the numerous claims and potentially resolve them more efficiently through a bankruptcy trust, offering a pathway to settle the massive litigation.

J&J’s “Texas two-step” strategy has faced significant legal challenges. The bankruptcy filings of LTL Management in New Jersey (after a change of venue) were twice dismissed by U.S. Bankruptcy Judge Michael Kaplan, a decision upheld by the Third Circuit Court of Appeals. The primary reason for these dismissals was the court’s finding that LTL was not in genuine “financial distress,” a key requirement for a good faith bankruptcy filing. The court emphasized J&J’s financial strength and its commitment to funding LTL’s obligations. These dismissals were viewed as significant setbacks for J&J’s strategy to resolve the talc litigation through bankruptcy.

Update: Federal Judge Allows Plaintiffs to Add J&J Affiliates as Defendants in Talc MDL, Potentially Hindering Future Bankruptcy Efforts

According to Law.com, U.S. District Judge Michael A. Shipp has rejected Johnson & Johnson’s bid to block plaintiffs from adding three affiliated companies—Kenvue Inc., Janssen Pharmaceuticals Inc., and Johnson & Johnson Holdco Inc.—as defendants in the federal talc multidistrict litigation (MDL) currently pending in New Jersey, which involves more than 65,000 lawsuits alleging its baby powder caused ovarian cancer. The ruling affirms a special master’s 2024 decision that plaintiffs had plausibly alleged that these companies acquired assets, continued operations, and effectively served as a “new hat” for Johnson & Johnson’s former consumer unit that made the powder.

The decision could significantly limit J&J’s ability to pursue another talc bankruptcy through asset restructuring and the “Texas two-step” maneuver, according to plaintiffs’ liaison counsel, Chris Placitella. J&J plans to seek dismissal of the claims after pending Daubert rulings, maintaining the allegations lack merit. The first MDL trial is expected next year.

J&J has faced three failed talc bankruptcy attempts since 2021, and the ruling echoes a similar decision in New Jersey state court allowing the same defendants to be added in related cases.

Despite the bankruptcy setbacks, the underlying talc litigation continues in various state and federal courts. J&J has pursued appeals of unfavorable verdicts, sometimes successfully. For instance, the Missouri Court of Appeals reduced the damages in the significant St. Louis verdict but upheld the finding that J&J’s products caused the plaintiffs’ injuries. The U.S. Supreme Court also declined to hear J&J’s appeal in a case brought by the Mississippi attorney general alleging failure to warn consumers about potential links between talc and ovarian cancer. These ongoing legal battles highlight the dynamic and unresolved nature of the litigation.

J&J’s legal strategies, particularly the “Texas two-step” bankruptcy, have drawn considerable scrutiny and criticism from legal experts, lawmakers, and victim advocates. Critics argue that this maneuver allows a financially healthy company to evade full accountability for its liabilities. There have been discussions about potential legislative measures to limit the use of such divisive mergers in mass tort cases. Furthermore, allegations that J&J concealed potential risks associated with its talc products for decades have fueled public outrage and legal challenges.

While initially resistant to broad settlements, J&J has entered into some agreements to resolve portions of the talc litigation. These include a significant settlement with numerous states over allegations of misleading marketing practices regarding the safety of its talc products and some individual and smaller group settlements.

However, a comprehensive global settlement that would resolve all outstanding claims has remained elusive, largely due to the complexities of the litigation and the differing perspectives on the value of the claims.

For law firms requiring experienced guidance in the complexities of mass tort settlement administration, Verus provides strategic settlement consulting services designed to help you and other stakeholders navigate these intricate processes and achieve optimal outcomes.

In 2020, Johnson & Johnson ceased the sale of its talc-based Baby Powder in the United States and Canada, citing declining sales and “misinformation” about the product’s safety. This decision, while framed as a market-driven move, was widely interpreted as a response to the mounting pressure from the litigation.

Litigation Update:  Massachusetts Jury Hits J&J With a Massive $42.6M Verdict in Talc Case

On July 29, 2025, in the largest mesothelioma verdict ever recorded in Massachusetts, a Boston jury has awarded Paul and Kathryn Lovell $42.6 million dollars, after determining that Mr. Lovell’s cancer was caused by his near-daily use of Johnson & Johnson Baby Powder over a 30-year period from the 1960s to the 1990s. Plaintiffs alleged that the baby powder had been contaminated with asbestos, a fact known by the defendant for decades. Mr. Lovell’s award was comprised of $15 million for past pain and suffering, $9 million for future pain and suffering, $608,300 for past medical expenses and $2 million for future medical expenses; the jury also awarded $5 million for past loss of consortium and $11 million for future loss of consortium to the plaintiff’s wife. In accordance with Massachusetts law, there were no punitive damages awarded,

Over the course of the two-week trial, counsel for the Lovells argued design defect, negligent design, inadequate warnings, and failure to warn, all of which they said caused the plaintiff to develop mesothelioma in 2021.  Plaintiffs also presented evidence including internal documents that established J&J’s awareness of the powder’s contamination; they also contended that the pharmaceutical giant manipulated methods and data to mislead consumers into believing the product was safe.

In addition, unlike many other plaintiffs, Mr. Lovell maintained that he had never had any other exposure to asbestos; addressing the causation factor, J&J contended that his peritoneal mesothelioma was caused by a rare gene alteration.

In response to the verdict Erik Haas, J&J’s Worldwide Vice President of Litigation said:

“We will immediately appeal this verdict, and, as with the vast majority of other plaintiff verdicts in the talc litigation, we fully expect the appellate court to reverse it. This decision is predicated on ‘junk science’ that is refuted by decades of studies demonstrating Johnson’s baby powder is safe, does not contain asbestos and does not cause cancer. The plaintiff lawyers’ business model is to roll the dice in search of jackpot verdicts, fueled by litigation-funded junk science, without regard to the fact that most claimants recover nothing in the tort system.”

To date, there is a complex framework surrounding the J&J talc product litigation. In March 2025, the company‘s third attempt at bankruptcy failed, with the court rejecting the strategy of creating a subsidiary, known as Red River Talc LLC, into which it attempted to channel all its talc liability. There is also a separate MDL with a total of over 60,000 cases filed by women who developed ovarian cancer after being exposed to J&J talc products; the first bellwether trial has been selected. Finally, cases continue to be tried in court with negative results for J&J, including the most recent $43 million verdict and another in June totaling $8 million.

In an earlier case, on June 18, 2025, a Massachusetts jury awarded $8 million to a woman suffering from mesothelioma that she alleged was caused by her years-long exposure to asbestos contamination in Johnson & Johnson’s talcum powder products. Janice Paluzzi alleged that she had used J&J’s Baby Powder and Shower to Shower products from the time she was a child; an expert witness testifying on her behalf also pointed to a trove of documents reflecting misleading statements made by J&J dating to the 1960s and 1970s in which the pharmaceutical giant maintained that its products never contained asbestos, despite extensive evidence to the contrary.

The defendant manufacturer countered, claiming that any asbestos exposure Ms. Paluzzi sustained would have come from family members who had worked around asbestos. J&J also noted that none of the bottles of product used by Ms. Paluzzi were ever tested.

The jury found that the talc products in fact did contain asbestos, a design defect that substantially contributed to her mesothelioma; they also found J&J liable for negligence in the products’ design. The award consisted of $5 million for past pain and suffering and $3 million for future pain and suffering.

Looking ahead, the future of the Johnson & Johnson talc litigation remains highly uncertain, with several potential pathways and ongoing challenges:

• Further Bankruptcy Strategies: J&J may explore additional bankruptcy filings, potentially in different jurisdictions, in an attempt to consolidate and resolve the outstanding claims. The success and legal challenges to these strategies will continue to shape the litigation’s trajectory.
• Continued Defense in Trials and Appeals: Despite bankruptcy maneuvers, J&J will likely continue to defend itself in the numerous individual lawsuits that proceed through state and federal court systems, as well as pursue appeals of unfavorable verdicts.
• Evolving Settlement Landscape: While a comprehensive global settlement has been elusive, the possibility of further partial settlements or a broader resolution agreement remains on the table, influenced by ongoing litigation outcomes and strategic negotiations.

The ultimate resolution of this extensive litigation will likely involve a complex interplay of these factors, with legal rulings, settlement negotiations, and evolving corporate strategies all playing significant roles.

Looking ahead, the future of the Johnson & Johnson talc litigation remains highly uncertain, with several potential pathways and ongoing challenges:

• Further Bankruptcy Strategies: J&J may explore additional bankruptcy filings, potentially in different jurisdictions, in an attempt to consolidate and resolve the outstanding claims. The success and legal challenges to these strategies will continue to shape the litigation’s trajectory.
• Continued Defense in Trials and Appeals: Despite bankruptcy maneuvers, J&J will likely continue to defend itself in the numerous individual lawsuits that proceed through state and federal court systems, as well as pursue appeals of unfavorable verdicts.
• Evolving Settlement Landscape: While a comprehensive global settlement has been elusive, the possibility of further partial settlements or a broader resolution agreement remains on the table, influenced by ongoing litigation outcomes and strategic negotiations.

The ultimate resolution of this extensive litigation will likely involve a complex interplay of these factors, with legal rulings, settlement negotiations, and evolving corporate strategies all playing significant roles.

The sheer scale and complexity of the J&J talc litigation underscore the indispensable role of sophisticated litigation support and claims management services. Managing tens of thousands of individual claims across multiple jurisdictions, handling voluminous discovery, coordinating with numerous law firms, and ensuring the accurate processing of potential settlements all require robust technological infrastructure, experienced personnel, and efficient workflows. 

Verus provides complex case management services with lessons learned from J&J litigation. Get assistance in areas such as centralized data management, claims administration, and analytics, enabling both plaintiffs’ and defense counsel to navigate the immense logistical and strategic challenges of this landmark case.